D Ross Camidge

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 22

Top Topics

Tyrosine Kinase

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer discovery

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa Lynne Johnson, Benjamin Besse, D Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Enriqueta Felip Font, Byoung Chul Cho, Luc Friboulet, Aaron N Hata, Henry E Pelish, Alexander E Drilon
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer discovery (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (25) (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Luke R G Pike, Emily Miao, Lillian A Boe, Tejas Patil, Brandon S Imber, Nathaniel J Myall, Erqi L Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica L Chiang, Michael Grant, Sarah B Goldberg, Joshua David Palmer, Rahul N Prasad, Tony J C Wang, Albert Lee, Catherine A Shu, Lanyi Nora Chen, Nicholas J Thomas, Steve E Braunstein, Brian D Kavanagh, D Ross Camidge, Chad G Rusthoven
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (25) (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Wade Goldman, Fedor V Moiseyenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer Kuch, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S Mansfield, Allen Chung-Cheng Huang, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (25) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
David Chun Cheong Tsui, D Ross Camidge, Chad G Rusthoven
Managing Central Nervous System Spread of Lung Cancer: The State of the Art. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (6) (2022)
D Ross Camidge, Fabrice Barlesi, Jonathan Wade Goldman, Daniel Morgensztern, Rebecca S Heist, Everett E Vokes, Alexander I Spira, Eric Angevin, Wu-Chou Su, David S Hong, John H Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Roy S Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Siu-Chung Chu, Isabelle Monnet, Alfredo Sánchez, Shaker Dakhil, D Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (29) (2022)
Alexander E Drilon, Michael Duruisseaux, Ji-Youn Han, Masaoki Ito, Christina J Falcon, Soo-Ryum Yang, Yonina R Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Ángel Molina-Vila, Marie Wislez, Philippe Brun, Clarisse Dupont, Eva Branden, Giulio Rossi, Alexa B Schrock, Siraj M Ali, Valérie Gounant, Fanny Magne, Torsten Gerriet Blum, Alison M Schram, Isabelle Monnet, Jin-Yuan Shih, Joshua K Sabari, Maurice Pérol, Viola W Zhu, Misako Nagasaka, Robert Doebele, D Ross Camidge, Maria Arcila, Sai-Hong Ignatius Ou, Denis Moro-Sibilot, Rafael Rosell, Lucia Anna Muscarella, Stephen V Liu, Jacques Cadranel
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (25) (2021)